Additionally, GBM was first exposed to hypoxia-induced MCT4 transcription activity and then treated with the HIF-1α inhibitor, which reversed the hypoxia-enhanced MCT4 expression (Figure 5B). Here, SLC16A3 is linked to glioblastoma.